Are you a
Lung cancer is the leading cause of cancer death in both men and women, with cigarette smoking causing the great majority of lung cancer cases. Quitting smoking is the only effective way for smokers to reduce their lung cancer risk, though former smokers who have abnormal cells in the lining of their breathing tubes are still at high risk for lung cancer. It is possible that abnormalities in these cells can be reversed with medication.
Iloprost in Preventing Lung Cancer in Former Smokers
Principal Investigator: York E Miller, M.D.
University of Colorado Denver
Doctors at the Denver VA Medical Center and University of Colorado have shown that the drug Iloprost may reverse some of the lung cell changes associated with future development of lung cancer. They are now testing an inhaled form of this drug (Ventavis®) in a clinical trial that is open to former smokers. Participants in the trial will be randomly assigned to receive either the drug or an inhaled placebo, so neither participants nor the investigators will know which treatment the participants are taking. The goal of this trial is to see if inhaled Iloprost may reverse abnormal lung cells and therefore prevent lung cancer.
We will enroll up to 50 participants in this study.
You may be eligible if you are:
A former smoker who quit smoking at least a year ago
You may be compensated up to $250 for participation in this study.
If you think you may be eligible, you can contact a study coordinator at your preferred location from the list below:
UNIVERSITY OF COLORADO DENVER - Denver, Colorado